Skip to main content

Table 2 Reliability of contrast features from the model for malignancy prediction

From: Characterization of a murine xenograft model for contrast agent development in breast lesion malignancy assessment

Contrast features (Method)

 

Accuracy

Sensitivity

Specificity

PPV

NPV

Molecular targeting contrast

CD31 (IHC)

100 %

100 %

100 %

100 %

100 %

VEGF (IHC)

100 %

100 %

100 %

100 %

100 %

Non-targeting contrast

Rim enhancement (DCE-MDCT)

93.5 %

95.7 %

91.3 %

91.7 %

95.5 %

Time-density curve

91.3 %

86.9 %

100 %

100 %

88.5 %

Washout T1/2 < 100 min (DCE-MDCT)

Endogenous contrast

Angular/ill-defined margin (grey scale US)

92.6 %

85.2 %

100 %

100 %

100 %

 

Angular/ill-defined margin (DCE-MDCT)

93.5 %

87 %

95.7 %

95.2 %

87 %

 

Orientation width/height > 2.2 (grey scale US)

100 %

100 %

100 %

100 %

100 %

 

Neovascular flow (color Doppler US)

57.4 %

14.8 %

100 %

100 %

54 %

  1. TPMDA = number of true positive (indicating malignancy) of MDA-MB 231 xenografts; TPMCF = number of true positive (indicating malignancy) of MCF-7 xenografts; TN = number of true negative (not indicating malignancy) of benign xenografts; FP = number of false positive (indicating malignancy) of benign xenografts; FNMDA = number of false negative (not indicating malignancy) of MDA-MB 231 xenografts; FNMCF = number of false negative (not indicating malignancy) of MCF-7 xenografts; accuracy = (TPMDA + TPMCF + TN)/(TPMDA + TPMCF + FNMDA + FNMCF + TN + FP) × 100 %; sensitivity = (TPMDA + TPMCF)/(TPMDA + TPMCF + FNMDA + FNMCF); specificity = TN/(TN + FP); PPV (positive predictive value) = (TPMDA + TPMCF)/(TPMDA + TPMCF + FP); NPV (negative predictive value) = (TN)/(FNMDA + FNMCF + TN); washout T1/2 = half-life of washout-like contrast pattern